Akili (AKLI) 7 Mar 232022 Q4 Earnings call transcript

Greetings, and welcome to the Akili Fourth Quarter 2022 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host, Julie DiCarlo, Senior Vice President of Communications.

Thanks, Joe. Good afternoon, and welcome to Akili's earnings conference call for the fourth quarter of 2022. today, on our of the closed can release, our market accessed be Investor the we earnings issued which website. After Relations section

our be reference of posted website and call the a we earnings conclusion the of today's our recorded, -- Additionally, teleconference IR of will at slides is being that on today's during on we'll replay call. available This event. our IR website

performance considered prospects of various certain make we'll risks statements future might or cause factors. forward-looking statements the differences materially by differ plans, or Factors any include, based those XX-Q involve today, our any the forth date. provided assumptions financial to, our as filings the set of with today's risks may such implied company. and During SEC. estimates today's but call, uncertainties November management are uncertainties. the limited events, as of regarding and forward-looking reasonable only subsequent be well any reflects such call on of These not actual as not and important expectations, upon company's as results We those on representative forward-looking X, filed statements are outlook. expressed other and of upon or that as views explicitly company's by that from should as forward-looking disclaim revise update obligation our while or The to result Form relied views Information any a our March in XX subsequent statements

slides financial complement to earnings accordance with A included in non-GAAP reconciliation GAAP greater provide of our to be but in in release. in results intend the substitute a financial non-GAAP to isolation our financial financial not or call, prepared our historical is presentation measures and does earnings today's as non-GAAP during Also refer the as Management certain we'll of measures considered measures these transparency. to GAAP, for measures. a

If you're please slides, to following the turn along now with the agenda.

and Shanbhag. Chief Medical Kollins; Akili's on today's Santosh are me Chief Matt With and Officer, call Financial Scott Operating Martucci, President our Officer, Chief Franklin; our our CEO, Eddie Officer,

turn remarks. I the Eddie hand X prepared Eddie? for to to please his Now call Slide as over

business everyone. of in Thank our about Scott various and of and call our last Julie. our Matt, summary on more evolving against execute QX to so our the Today, traction expect from we We're business, increasing we generally, Hello, operating capital business XXXX. the discuss With for more year EndeavorRx excited our business progress aspects business you QX now that you'll and with joining and detailed to important most in that have we're efficient business our growth. seeing model. QX Thanks, cash announced overall of moves of XXXX. goals performance hear early that Santosh how year fund business we footprint the of and of into the a will this we're restructure can

strong force drug. commercial metrics. I'm focused I out marketplace, focus out a the pocket passionate most digital treatment the of also the be in willingness we're by and believe, our scale happen. indeed EndeavorRx impact is and the the pay increase prove making entire first investment, With positive can has we'll this excited our of that the to patients. to a that with example new team early Akili seeing sales We're on seeing where ADHD look EndeavorRx potential heightened on of in paradigm like to

last quarter. patient companion cutting continue our to medicine of and product both the to seen caregiver push edge insurers to As enhancements broader And a we experience a is this coverage, haven't focus step for us. our up and continued with of treatment the in expected, area multiple product over we

STARS-ADHD-Adolescent to In patients product, positive than believe year. were from of benefit to of of can our in this ADHD getting announce earlier terms extremely outcomes all excited our EndeavorRx we trial we from anticipated the January

and double in this submission year putting include EndeavorRx of planned urgency expanded medication adolescents label our we're ongoing needs estimates. would on addressable ADHD the review for the successful, around current an market our teens mental shortage, With over If to based XX for around of label health FDA a that age. expanded years essentially our

pleased increased look made in the progress and Matt? we've Matt and into to Franklin, execution President give core good our focus mindset turn I'm part with believe it the more over early of you I team's and end year, our I'll to Overall, COO, to business now even here deeper our XXXX. a progress.

Eddie. Thanks,

outlined strategic our are X business. we of quarter These third earnings our for X. focus outlined areas on call, Slide During

The opportunity EndeavorRx first for XX force sales in driving of EndeavorRx. market estimated in is adoption covering the first is of XX% roughly the awareness the of of direct our U.S. addition wave territories priority

expanded progress experience. barriers driving for we adoption and is experience. aim by our expanding continually quarter, fourth with the coverage third, made removing second we and improving adoption good The the to to treatment improve EndeavorRx, In treatment

continue expected, to a coverage act challenge payers be and remains on. addressing are that slow As head we to

sales third our priority we approximately wave territories geographic Let's first each to these look in with of XX the initial of the identified deployed adoption. areas, starting we at team XX U.S. the quarter, territories of In the

are growth in growth, overall per overall or in We the initial territories by encouraged whitespace geographies of the occupied these progress number outperformed territories. of in end and active sales prescription prescriptions unoccupied XXXX, the prescriber. of seen prescribers Through number we've

of who per XXX multiple the repeat by prescriptions there of In was This metrics. expanding than more prescribers area growth our performance for and number and sales we've sales repeat add engagement believe XXXX. QX between accelerated across prescribers strong in key grow time. team, seen short, have we simultaneously month is a correlation XX% a focus direct over meaning adoption over key prescribers, to written new while QX, prescribers continue We

force during transition This QX, EndeavorRx, the driven a quarter August. the was for prescription, on direct saw seeing initiated by we EndeavorRX the In XX-day to XX-day which refill from addition of third of in was also over XXX% than growth to successful growth more initial demand impact prescription prescriptions of our sales the XXXX.

transition, to expect XX-day now of quarter. these saw this an course. prescription XX the XX% of a is we we the commercial in periodic working therapy. that dispensed the XX-day expanding additional established maintained and Seeing this quarter, prescriptions U.S. higher that be which in prior During only we price, with applies per as end are early treatment list EndeavorRx model price, the us approximately is this Even force giving by ongoing our $XXX confidence effective month reduction to markets sales indicators traction, and from

families new this willing options pay now rapidly coverage. this QX, than for access non-pharmaceutical out providing, to is continued more continue barrier payers to our we Moving expanded for and EndeavorRX, pocket In we them. acknowledge encouraging, are we treatment need to currently while to see of that breakdown to families work

experience as able the nature therapeutics while the Finally, last preserving rapidly of patients iterate opportunity product. shared a video we core on by experience, are engagement to of quarter, and to compliance. ability unique have we the Enabled play the digital for with and the drive adaptive dynamic we the treatment game product games, regulated technology evolve EndeavorRx to of

Insight. including companion our optimize surrounding the to application continue EndeavorRx and product, treatment update experience the caregivers also for We

This to on treatment. enhancements were patient player improving tracking into In core engagement to QX, and is patient visibility of ongoing on-boarding their to play our and amazing our increased game progress the experiences during progress provide to our families. optimizing caregivers commitment and providers focused experience, deliver implementing maximize features patients healthcare part

Turning X, let's the look now to at numbers. Slide

First, prescriptions on prescriptions, were in written for XXXX. more than X,XXX EndeavorRX

mentioned to a increase XXX% quarter, XXXX. were during over XXXX XXXX increase on in up in There XXXX, XXX% saw the There over prescription we the a QX written QX over during a QX up than for number significant XXXX despite X,XXX prescriptions written QX from number QX more in also X On the than prescriptions selling written during written EndeavorRx, QX were during XXX we X,XXX QX the During XX% written XXX% over period, QX refills, refills a period. as XXXX the about about period, earlier, fewer XXXX. fourth the increase new representing more days refills XXXX. of prescriptions saw and XXX% and similar increase

from number number this from QX were by prescriptions QX, offset prescribers, of X% XXX down increase written QX more were prescribers from in prescribers, written XX% more down key which than QX repeat of number XX% decline for dispensed XXXX. increase On a of growth XX% team, the sales the in XXXX. was XXXX, saw QX of XX% but prescriptions prescribers, total an XX% of new than area XXXX, in our QX of representing but QX in grew the by we unique in over from during QX was quarter, over The XXXX. focus new up a XX%

We XX-day believe transition was driven impact holidays. XX-day and two this to the prescription from a the factors: of by December the

qualifying for received charge out our X% assistance pocket XX% XX% prescriptions prescriptions. under dispensed by reimbursed of to program. payment of provided QX, dispensed of we were families and patient free paid were During of caregivers, were X%

our I'll an provide Dr. it Officer, on programs. turn Now Chief our Scott Medical Kollins, clinical over to will update who

Akili I'm on since to everyone. excited joining be joining first Hello, Matt. my Thanks, earnings X. call December

and not patients benefit. leading care product entire of to my now I change transition career to standard patient fact to quick for company. since a of years FDA-authorized we new have not graduate we XX-year medical ADHD, this spent options decades. at into running be EndeavorRx, the product treatments in started, the that and work get my studying XX including The as have can aspects University get grown excited I to that, the on the the I'm Before have an hands everyone for school. can nearly and note who has changed of Akili new program ADHD Duke we in provided I've that scientific finished

the and care. my of efforts important supporting component Broadly, will for an disseminate strategy commercial continuing safety EndeavorRx effectiveness of evidence generate on ADHD and high-quality primarily focus is to team by clinical of our current the

reminder, a with of coincide subsequent made activities additional strategic resources development decision we've on will a capital the product or growth our focus As development clinical business EndeavorRx raise ADHD for to opportunities. and our

our with where are I'll ADHD provide Turning now clinical Slide to on update an programs. we X,

As XX results study our this in adolescents. results expansion ADHD early strongly age January line in and trial of and of from year, we have the of with XXX now efficacy pivotal the XX, EndeavorRx patients we safety STARS-ADHD-Adolescents to reported label EndeavorRx, top support

children. measures, the that in to equal These were findings for in process of or measures this you can our the younger to outcome X peer-reviewed this to current in As country to our mental on is presentation seen and magnitude teenagers. pivotal XXX(k) health see given a than across ADHD timely adolescent attentional crisis for to and future greater of to expand the preparing FDA a meeting of range growing We're for we've symptoms the to are study and EndeavorRx. disproportionately submission effect the studies objective use including slide, of label previous functioning support findings in We're scientific potentially track on submission year study journal. from affecting results those

Referring we pipeline was our adults reported more study for earnings shared recruiting in this that Slide We on we to slowly enrollment our stopped than pivotal that on previously with expected. study of STARS-ADHD-Adults, ADHD. call also last EndeavorRx our X,

enrollment I to number that results analyze in than strong from top this which capital the this enrolled adolescents The Data adolescent and Given XXX the in for have just this study patients, study we second closed ongoing, enrolled is study. adult data. of preserve in described, and that analysis the study more stated is XXXX. data adult line in study expect we the we to adult the half clinical

decision later as relates our this the regulatory strategy STARS-ADHD-Adult We about a to study. expect year to make it

adolescent registry In pivotal market collect completion addition that our will into access also real-world we're to adult allow other to the us participants and support studies, of a to and regulatory data enrolling initiatives. actively

de-prioritize outside of significant that other additional January, chosen in ADHD, investment. would require we've As announced clinical to programs

analysis launched finalized, in we previously QX. continuing of are Data collaborative the process second in enrollment infection. X include complete one of studies, study in is EndeavorRx for following to treat the We being cognitive studies to studies expect investigator-initiated and which and these impairments of patients COVID

As both studies the of from readout QX. by to such, data we expect end

CFO, our to I'll hand over it now Santosh Shanbhag.

you, hello, everyone. and Thank Scott,

#X. Now to on Slide on the financials

our earlier, the sales continue to in field. also reps the Matt growth of see revenues. of And the We quarter-over-quarter EndeavorRx as positive we mentioned wave are first impact seeing of

of XXXX quarter year over up of fourth of XX% Note XXXX. that with an $XXX,XXX, Similarly, XXXX USDXXX,XXX EndeavorRx a revenues the growth XXXX XX% in slide, of of the the fourth $XXX,XXX, full revenues representing XXXX. in collaboration. EndeavorRx respectively, in and the QX XXXX, and on USDXX,XXX, revenues see you As revenues the quarter from growth third Shionogi grew to a over to grew $XXX,XXX and included total additional associated quarter XXXX

we expenses total operating an primarily was combination $XX non-GAAP EndeavorRx, perspective, approximately to million the XXXX costs expense growth operating Similarly, GAAP compared expansion business commercial with the The $XX the total and expenses compared expenses incurred short-term GAAP expenses operating million cash, $XX but and From quarter of label driven and associated investments. growth related approximately of a the in business studies EndeavorRx. XXXX. we least, total quarter third the the $XXX expenses commercial support fourth by million incurred to in operating ADHD with and of primarily related company. quarter also of of of the And the was launch support third to to last driven a public by of million non-GAAP launch of about as of expenses XXXX. equivalents the $XX in ended expenses million and expenses year XXXX perspective, not we cash of capital operating of The approximately from

to on Slide Now on #XX. guidance

this compared our XX plan, XXXX represents approximately XX% expect In impacting non-GAAP to company approximately support of guidance operating USD that We reduction of non-GAAP XXXX expenses our million. million. expenses expense and the employees January reduction operating are reaffirming total of This from be underwent We we between a operating our a across XX current Please termination-related XXXX operating to XXXX to costs, USD the $XX expense record the million total in severance workforce incur the organization. compensation termination-related total to will expect to of in these action to these addition during costs $X.X estimate quarter related year from million are excluded and the that and and guidance. about note we that full charges $X.X stock-based severance QX. projected non-GAAP million

me This plans. our capital brings to

We in runway previously have reaffirming are we guidance cash announced that January. also the

cash with to on at and our position the of expect million our XXXX quarter to I'll close We the able year-end current financial XXXX. $XXX be operations planned into fund update this. first approximately of

our and plan expansion; to: XXXX operating especially primarily label preserve market current in these us resources capital, commercialization Our and allows focus one, on capital ADHD EndeavorRx X, conditions.

back I'll With that, hand it over to Eddie. Eddie?

Thanks, Santosh.

key like I all our XXXX. to obviously, the first from we've the And data expand and Slide can from to turn quarter. Overall, to increasing If seeing EndeavorRx you'd had to XX, the with into you label, We the regulatory submission. excited we're by we line traction quarter. top moving see our strong EndeavorRx. positive announced trial We're runway pivotal forward think with we're us this takeaways a as cash designed noted, business structured give

I'll we're to it and back that, hand happy questions. take operator, With to the

Judah line with from Credit [Operator Our the first question Frommer of Instructions] comes Suisse.

on incremental was for you gap could patients just are hoping getting there refills, prescriptions? Judah average? time on the many Suisse. able provide on And that you refills how getting they refills. guys between if is I insight Nick for are any from share, Are is to Congrats This some those on Credit progress.

question. the there. A appreciate couple This I is Matt. comments of

significant to, in business QX. I changes we in as First, we made -- mean announced, two QX

the change around in of to prescription discussions First our where retail XX-day prescriptions. direct from sales force, we're was the XX-day and addition engaging

bit would two retail give we see those how more to to evolve. the with significant little time business love patterns So changes, a

share with state, are are however, of and that providing So point we're written, majority specific at the refills. vast prescriptions written guidance. multiple I not that can this

retail for a an X often time. of a So be new initial over prescription treatment, child cycle multiple and is written with X, or includes that more could

expect increases over So to time. we do refills continued see in

about at quickly. very or kind And the a Nick, question asked add, I'll end sequential nature of you just how

meant out. something and are that's in treatment, ongoing As an or sequentially the is be we immediately we've and bounce And before, or ongoing episodic that in may to seeing EndeavorRX right, market. may said come used

we terms with immediate in do a see into their they're when after and do getting some and come gap we behavior. their metrics, of doctors. without back So symptoms And refill in patients refills, see time reassessing specifics who then

So scale. I given think new will this is evolve something a to treatment will that new we continue this modality really with is as It evolve dynamics.

of Michael with comes of question line Bank next Our Cherny from the America.

candidates. we product going after business, little the think I for se, docs, the docs terms on think strategic what if dive new what your do especially 'XX you can going per versus into in Maybe on And you each bit dynamics, the one is, after revenue you retrenching gets expectations core et about how guess, of How retention of focusing existing that of have a of incorporated those more about as guidance returning balance docs? cetera? is don't but penetrated the prescriber

Matt. it's crack Thanks, take that. a to happy Michael. I'm at Again, first

the appreciate you sales our -- I our focus initial we prescription on as So guess, as force, deployed question. our driving here overall can growth. is QX

those providers. team reengaging we areas those with back the So engaging the in territories prescribers one with initially on newly of historical those sales and that focused populated going with is

and you in We significant prescribers. refill in a So an did saw increase, of jump that on We historical emphasis prescriptions. we that repeat place growth intentionally XX% the reengaging saw providers strategy. saw XXX% benefits

of we the that So initial with results strategy. were pleased

a been Now balanced quarter, taken approach. in a team that more has the for we've the field

new see prescriptions spend balancing engaging, over and those providers. we educating prescribers new writers to with expect that we time. time and the balancing grow do existing So And servicing new

but coverage as milestones looking think you expansion, obviously in you that relative focus candidate on could have redefine the a to in within a general coverage how side, model covered given landscape? candidates to a payer about current also in you're -- new if from continue doesn't bit you're do dive commercial just obviously, side, for you to on have coverage the having -- and broad pipeline And the therapeutics necessarily the I given the digital that

Sure. is Michael. This Thanks, Eddie.

sufficient. class pleased digital When think seen that as dig therapeutics -- prescription data, that have. is teams because clinical we absolutely. of seeing kind clinical digital seeing I our this yet, we're hasn't run interactions And right for We're impressed have a of broad you're with we we the coverage So they're in multiple this clinical data obviously, program. the payers, get that We're level prospective with engagement. with the feedback we've generally, trials therapeutics

guiding So not of we're covered number lives not announce -- don't on and we coverages coverages. things We're on guiding like on expectations that. individual or or

milestones perspective, our payer educate are essentially this the on landscape product. to the From work really this doing

more, broadly, by they I think our our here more because aware, data, surface I our going see of into success, very is that's where and going deeper data outcomes date. are what generally like to the of investment to the see and to payers believe we start that are in level because product product we're

doing really takes is of milestones which with internal these each doing it's deep to So those the time. really go stacking work up meetings payers,

of Capital. comes with Our the Rakhit from next question LifeSci Rahul line

was shape wondering patients adoption commercial existing will ultimately from feedback the data, prescriber Given pretty adolescent launch? how I upon And amongst do clearance that and adolescent what think feedback, was that you your also base? impressive the

Yes. is this Rahul, Scott.

So We them. announced just it's early.

population. access the to published, providers that mean yet a data is or We an get from the I It's double going talk general that number very haven't effective as we to very reaction else positive. as of this presented to everybody underserved can is well kids but treatment. the

positive. overwhelmingly been has reaction the So

Got it.

than you are That's to there of terms sales just in areas how guess Or And terms trying expanding thinking then in you territories possible with any are coverage? growth? the which into territories. think your guys existing that is as expand into, script driving going cash to Okay. I of know this helpful. I wider around reimbursement you

density. terms number launches. a frequent factors at pharmaceutical, overall biotech, small right, look Matt. on would it's medical addressable I patient sure prescriber at well, to to of at a these reach enough boundaries similar device as We can We We other are of Yes, Rahul, get these look basis, geographic it's and frequency. physicians that we population. making where look that to really maintain imagine Yes, in opportunity consider. that we

of we're So terms do it I The do, thing is, with think one do at integrate market access we sales our in looking we our opportunity. strategy.

the have with that commercial those So force. sales we existing are areas in engaging plans we

So pull it we're through. able to

Highmark. example, active do Pennsylvania. presence call, sales For have We about last talked we in

again, aspects an different integrating just of our how example, we're of So commercial these team. all

one new coming That's wondering touch And of it. it. website more on I guess Got really kind that me. the your sales I portion the was ground? just for just through versus you appreciate to platform of patients I could in telemedicine your on helpful. if the are force

provided our we what capability. but We're to Yes, haven't to contributor specific I be, guidance. that meaningful modest Telemedicine a we that have say, pleased prescription would continues volume.

be more so more may as we population, that. I expand the follow-on to into adult think it important

comes of Purohit Our with Stanley. question Vikram line next Morgan the from

Two side, EndeavorRx. commercial on from our efforts your with both

I they them and in you when your XQ. initial of on effort, helping scripts their I of condition you end hasn't present of and in reported increase phase and secondly, to EndeavorRx? So reflect profile what the of status status in of specifically overall aspects who EndeavorRx prescribing And to that eventually do think so you in are to demonstrating what's are patients when what up resonated quarter-over-quarter your their the terms really like first, efforts think you typical pretreatment which the that do far? commercialization is receptivity messaging the drive providers guess, mean, commercialization the

to Again, question. address the to me don't keep forget sure my for Thanks that I'll right. Matt. make best do question, it's any. I All honest multipart

studied is that that the on one that, the into things and combination child been been as profiles, a first, team's fit as with effective can think treatment the I any right, investment in has made of really physician be EndeavorRx conjunction appreciate the pipeline input. and to clinical demonstrated patient standalone the it I in caregivers and therapy, as plan, medical and the seamlessly with treatment well it both about

it's flexible. said, see out. that our early really With patient to very stand in So profiles engagements do we

diagnosed The first patients. is newly

or So caregiver non-pharmaceutical in those exploring who been interested who is in a exploring treatment. recently have diagnosed are interested

the first. that's So

Second area for we're and medical seeing are these not demand patients that side of be options. effects the with often a drugs, lot those on they that alternate therapy stimulants controlled well non-pharmaceutical is come prescription experiencing may are that looking to explore

are So been use or discuss have if those physicians really profiles the of areas. cases, will, uptake. interest patient as area those we you Those two with and an

our So clinical data, I flexibility demonstrating the therapy treatments the standalone in the of have or as been demonstrating a compelling. think going conjunction very impact through

highlight sort -- from we're getting the the would of the are those So team. initial I just feedback

Our of the question Marie from BTIG. next line comes Thibault with

to fourth of have that like in the is space. still refill, so XX-day you're our that's looks certainly how by also conversion a there. refill nice I holidays understand, or certainly, prescription mentioned we And wanted rate high the in to drove I that XX% know a in here to then I couple to rate. the are wanted won't QX, I like expecting headwinds the rate wanted know you down the to that improve ask QX? in here conversion I on my you XX%. It thinking quarter about that first but understand, factor the XX-day math. we did

forward? be conversion we resales going should thinking for about how Just

Yes. Thanks, Marie.

forecast the or conversion. guidance provided not regarding have We

constant. As being another is impact. you to two mentioned, that changes, XX impact. was XX-day The pricing prescription biggest migration from there That the were while holding holiday seasonal business the an

of said, that is With again team. our will QX. for this persist an in area Of course, sales that not also emphasis

So are areas we're talking and and with clinicians, those that have where patients we the making the prepared. sure importance ability of engage caregivers to in follow-up about

doing of to and giving best prepared far time. at fulfilling continue message prescriptions. guidance, not to the this do that to educate are those we So as importance our But we're as around

Okay.

high-XXs is I but initial refills. of it early, know those on built range? around Just something given we is reasonable that into the sort prescription, expect a that are should the

we changes. Again, I mean, early the days. business estimate

guidance on to we're hesitant So provide that.

Okay. question I'll a of further on sales sort Fair force. maybe ask And enough. then the

As key thinking Is next process months -- wave about the adding maturation enter we of the about the for on new the profile, target? in the kind should the prescriber kind this here a quarter, territories? of is first as is a kind what who year-long these caregiver learnings who they And you're how profile of sales sales think right reps is this to force? right six of

the said, has Thanks we're progress still a the And a are team early in launch, particularly for pleased days. learning question. that we're we and as absolutely product consistent with experience any category very Yes. that there's where defining seeing. a EndeavorRx, situation We're new been are The we with really with With for relatively curve. in field several months.

critical seeing mentioned, we territories. sales adoption we're growth those of metrics commercial all accelerated As in on their and

Initially, So to pleased improvement there. expect will with what we continued see we're continue -- seeing. we

and there that say, yet, wouldn't we're I we're through working that learning learn So curve, grow, to we're effectively. continuing but

with as indication, initial XX-year-olds, the to our As specialty. surprisingly, not pediatric we're focused profile, consistent yes, on physician X far

see pediatric that time. pediatric for monitoring over general neurologists, So psychiatrists, are a PD number to large of in responsible attritions a these addition and number patients

complex really centers, where of So sort with these day impairments multidisciplinary day cognitive basis. they're a practices integrated on out those behavioral dealing on in, focused health

focus of So consistent initial for remains and that a point emphasis us. perspective from was our

with Judah again Credit come question line Frommer Suisse. of from will the next our And

on for again. Nick Judah It's

go design specific was it higher do translate population? versus something efficacy population And initial on data, And how back adults? in wanted the Just that the any adolescent just to the X that or thoughts you think why to to initial attention XX-year was to the on do might effect with into olds. trial

question. it's the Nick, very Scott. this a one. Yes, Thanks is for good

hypotheses of magnitude we about We adolescents. the greater why broad a might seen couple have have in effect

likely top going The line, make in might at at. gender a some first the pretty or That's the ethnic are subgroups and think to compared it be But we're things looking more interrogate just would more benefit. population. Older that kids difference. participants do where to of of is the breakdown like the look treatment uncover doesn't the engaged with effect I that way maybe they like pediatric and the is to had to derive differences, the the we engaged that therefore, And the least at that going to be easy more the something with racial look composition treatment. motivated is further, in sample with understanding with to much of

is an that the far as know diving line And into be area and unknown, think study. data that So it's we and how as for prepare get might that from we're further. well the we'll extrapolate, -- as top adult presentation we when data to that we going publication

Thank conference. our today's gentlemen, this and session, question-and-answer this you. will Ladies concludes and conclude

your participation. your You for you may disconnect lines this at time. Thank